aluates Reports

$ 0.0

Automative

Global Tumor Immunotherapy Market Research Report 2024

Published Date: May 2024

Report Code: QYRE-Auto-18E7950

Global Tumor Immunotherapy Market Insights and Forecast to 2028

BUY CHAPTERS

Global Tumor Immunotherapy Market Research Report 2024

Code: QYRE-Auto-18E7950

Report

May 2024

Pages:101

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

Tumor Immunotherapy Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Tumor Immunotherapy Market

The global Tumor Immunotherapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Tumor Immunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Immunotherapy.

Report Scope

The Tumor Immunotherapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tumor Immunotherapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Tumor Immunotherapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Tumor Immunotherapy Market Report

Report Metric	Details
Report Name	Tumor Immunotherapy Market
CAGR	5%
Segment by Type	Tumor Infiltrating Lymphocyte (TIL) Treatment Engineered T Cell Receptor (TCR) Therapy Chimeric Antigen Receptor (CAR) T Cell Therapy Natural Killer (NK) Cell Therapy Other
Segment by Application	Biopharmaceutical Company Hospital Universities And Other Scientific Research Institutions Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Merck, Novartis, Johnson & Johnson, GlaxoSmithKline, AbbVie, ELI Lilly, Amgen, AstraZeneca, Bristol-Mysers Squibb, Kite Pharma, Adaptimmune, Altor Bioscience Corporation, Cellectis, Juno Therapeutics, Takara Bio, Unum Therapeutics, Sunway, Junshi Bio, Cinda Bio, BeiGene
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tumor Immunotherapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Tumor Immunotherapy Market report?

Ans: The main players in the Tumor Immunotherapy Market are Roche, Merck, Novartis, Johnson & Johnson, GlaxoSmithKline, AbbVie, ELI Lilly, Amgen, AstraZeneca, Bristol-Mysers Squibb, Kite Pharma, Adaptimmune, Altor Bioscience Corporation, Cellectis, Juno Therapeutics, Takara Bio, Unum Therapeutics, Sunway, Junshi Bio, Cinda Bio, BeiGene

What are the Application segmentation covered in the Tumor Immunotherapy Market report?

Ans: The Applications covered in the Tumor Immunotherapy Market report are Biopharmaceutical Company, Hospital, Universities And Other Scientific Research Institutions, Other

What are the Type segmentation covered in the Tumor Immunotherapy Market report?

Ans: The Types covered in the Tumor Immunotherapy Market report are Tumor Infiltrating Lymphocyte (TIL) Treatment, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Tumor Immunotherapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Tumor Infiltrating Lymphocyte (TIL) Treatment

1.2.3 Engineered T Cell Receptor (TCR) Therapy

1.2.4 Chimeric Antigen Receptor (CAR) T Cell Therapy

1.2.5 Natural Killer (NK) Cell Therapy

1.2.6 Other

1.3 Market by Application

1.3.1 Global Tumor Immunotherapy Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Biopharmaceutical Company

1.3.3 Hospital

1.3.4 Universities And Other Scientific Research Institutions

1.3.5 Other

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Tumor Immunotherapy Market Perspective (2019-2030)

2.2 Tumor Immunotherapy Growth Trends by Region

2.2.1 Global Tumor Immunotherapy Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Tumor Immunotherapy Historic Market Size by Region (2019-2024)

2.2.3 Tumor Immunotherapy Forecasted Market Size by Region (2025-2030)

2.3 Tumor Immunotherapy Market Dynamics

2.3.1 Tumor Immunotherapy Industry Trends

2.3.2 Tumor Immunotherapy Market Drivers

2.3.3 Tumor Immunotherapy Market Challenges

2.3.4 Tumor Immunotherapy Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Tumor Immunotherapy Players by Revenue

3.1.1 Global Top Tumor Immunotherapy Players by Revenue (2019-2024)

3.1.2 Global Tumor Immunotherapy Revenue Market Share by Players (2019-2024)

3.2 Global Tumor Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Tumor Immunotherapy Revenue

3.4 Global Tumor Immunotherapy Market Concentration Ratio

3.4.1 Global Tumor Immunotherapy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Tumor Immunotherapy Revenue in 2023

3.5 Tumor Immunotherapy Key Players Head office and Area Served

3.6 Key Players Tumor Immunotherapy Product Solution and Service

3.7 Date of Enter into Tumor Immunotherapy Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Tumor Immunotherapy Breakdown Data by Type

4.1 Global Tumor Immunotherapy Historic Market Size by Type (2019-2024)

4.2 Global Tumor Immunotherapy Forecasted Market Size by Type (2025-2030)

5 Tumor Immunotherapy Breakdown Data by Application

5.1 Global Tumor Immunotherapy Historic Market Size by Application (2019-2024)

5.2 Global Tumor Immunotherapy Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Tumor Immunotherapy Market Size (2019-2030)

6.2 North America Tumor Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Tumor Immunotherapy Market Size by Country (2019-2024)

6.4 North America Tumor Immunotherapy Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Tumor Immunotherapy Market Size (2019-2030)

7.2 Europe Tumor Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Tumor Immunotherapy Market Size by Country (2019-2024)

7.4 Europe Tumor Immunotherapy Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Tumor Immunotherapy Market Size (2019-2030)

8.2 Asia-Pacific Tumor Immunotherapy Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Tumor Immunotherapy Market Size by Region (2019-2024)

8.4 Asia-Pacific Tumor Immunotherapy Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Tumor Immunotherapy Market Size (2019-2030)

9.2 Latin America Tumor Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Tumor Immunotherapy Market Size by Country (2019-2024)

9.4 Latin America Tumor Immunotherapy Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Tumor Immunotherapy Market Size (2019-2030)

10.2 Middle East & Africa Tumor Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Tumor Immunotherapy Market Size by Country (2019-2024)

10.4 Middle East & Africa Tumor Immunotherapy Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Roche

11.1.1 Roche Company Detail

11.1.2 Roche Business Overview

11.1.3 Roche Tumor Immunotherapy Introduction

11.1.4 Roche Revenue in Tumor Immunotherapy Business (2019-2024)

11.1.5 Roche Recent Development

11.2 Merck

11.2.1 Merck Company Detail

11.2.2 Merck Business Overview

11.2.3 Merck Tumor Immunotherapy Introduction

11.2.4 Merck Revenue in Tumor Immunotherapy Business (2019-2024)

11.2.5 Merck Recent Development

11.3 Novartis

11.3.1 Novartis Company Detail

11.3.2 Novartis Business Overview

11.3.3 Novartis Tumor Immunotherapy Introduction

11.3.4 Novartis Revenue in Tumor Immunotherapy Business (2019-2024)

11.3.5 Novartis Recent Development

11.4 Johnson & Johnson

11.4.1 Johnson & Johnson Company Detail

11.4.2 Johnson & Johnson Business Overview

11.4.3 Johnson & Johnson Tumor Immunotherapy Introduction

11.4.4 Johnson & Johnson Revenue in Tumor Immunotherapy Business (2019-2024)

11.4.5 Johnson & Johnson Recent Development

11.5 GlaxoSmithKline

11.5.1 GlaxoSmithKline Company Detail

11.5.2 GlaxoSmithKline Business Overview

11.5.3 GlaxoSmithKline Tumor Immunotherapy Introduction

11.5.4 GlaxoSmithKline Revenue in Tumor Immunotherapy Business (2019-2024)

11.5.5 GlaxoSmithKline Recent Development

11.6 AbbVie

11.6.1 AbbVie Company Detail

11.6.2 AbbVie Business Overview

11.6.3 AbbVie Tumor Immunotherapy Introduction

11.6.4 AbbVie Revenue in Tumor Immunotherapy Business (2019-2024)

11.6.5 AbbVie Recent Development

11.7 ELI Lilly

11.7.1 ELI Lilly Company Detail

11.7.2 ELI Lilly Business Overview

11.7.3 ELI Lilly Tumor Immunotherapy Introduction

11.7.4 ELI Lilly Revenue in Tumor Immunotherapy Business (2019-2024)

11.7.5 ELI Lilly Recent Development

11.8 Amgen

11.8.1 Amgen Company Detail

11.8.2 Amgen Business Overview

11.8.3 Amgen Tumor Immunotherapy Introduction

11.8.4 Amgen Revenue in Tumor Immunotherapy Business (2019-2024)

11.8.5 Amgen Recent Development

11.9 AstraZeneca

11.9.1 AstraZeneca Company Detail

11.9.2 AstraZeneca Business Overview

11.9.3 AstraZeneca Tumor Immunotherapy Introduction

11.9.4 AstraZeneca Revenue in Tumor Immunotherapy Business (2019-2024)

11.9.5 AstraZeneca Recent Development

11.10 Bristol-Mysers Squibb

11.10.1 Bristol-Mysers Squibb Company Detail

11.10.2 Bristol-Mysers Squibb Business Overview

11.10.3 Bristol-Mysers Squibb Tumor Immunotherapy Introduction

11.10.4 Bristol-Mysers Squibb Revenue in Tumor Immunotherapy Business (2019-2024)

11.10.5 Bristol-Mysers Squibb Recent Development

11.11 Kite Pharma

11.11.1 Kite Pharma Company Detail

11.11.2 Kite Pharma Business Overview

11.11.3 Kite Pharma Tumor Immunotherapy Introduction

11.11.4 Kite Pharma Revenue in Tumor Immunotherapy Business (2019-2024)

11.11.5 Kite Pharma Recent Development

11.12 Adaptimmune

11.12.1 Adaptimmune Company Detail

11.12.2 Adaptimmune Business Overview

11.12.3 Adaptimmune Tumor Immunotherapy Introduction

11.12.4 Adaptimmune Revenue in Tumor Immunotherapy Business (2019-2024)

11.12.5 Adaptimmune Recent Development

11.13 Altor Bioscience Corporation

11.13.1 Altor Bioscience Corporation Company Detail

11.13.2 Altor Bioscience Corporation Business Overview

11.13.3 Altor Bioscience Corporation Tumor Immunotherapy Introduction

11.13.4 Altor Bioscience Corporation Revenue in Tumor Immunotherapy Business (2019-2024)

11.13.5 Altor Bioscience Corporation Recent Development

11.14 Cellectis

11.14.1 Cellectis Company Detail

11.14.2 Cellectis Business Overview

11.14.3 Cellectis Tumor Immunotherapy Introduction

11.14.4 Cellectis Revenue in Tumor Immunotherapy Business (2019-2024)

11.14.5 Cellectis Recent Development

11.15 Juno Therapeutics

11.15.1 Juno Therapeutics Company Detail

11.15.2 Juno Therapeutics Business Overview

11.15.3 Juno Therapeutics Tumor Immunotherapy Introduction

11.15.4 Juno Therapeutics Revenue in Tumor Immunotherapy Business (2019-2024)

11.15.5 Juno Therapeutics Recent Development

11.16 Takara Bio

11.16.1 Takara Bio Company Detail

11.16.2 Takara Bio Business Overview

11.16.3 Takara Bio Tumor Immunotherapy Introduction

11.16.4 Takara Bio Revenue in Tumor Immunotherapy Business (2019-2024)

11.16.5 Takara Bio Recent Development

11.17 Unum Therapeutics

11.17.1 Unum Therapeutics Company Detail

11.17.2 Unum Therapeutics Business Overview

11.17.3 Unum Therapeutics Tumor Immunotherapy Introduction

11.17.4 Unum Therapeutics Revenue in Tumor Immunotherapy Business (2019-2024)

11.17.5 Unum Therapeutics Recent Development

11.18 Sunway

11.18.1 Sunway Company Detail

11.18.2 Sunway Business Overview

11.18.3 Sunway Tumor Immunotherapy Introduction

11.18.4 Sunway Revenue in Tumor Immunotherapy Business (2019-2024)

11.18.5 Sunway Recent Development

11.19 Junshi Bio

11.19.1 Junshi Bio Company Detail

11.19.2 Junshi Bio Business Overview

11.19.3 Junshi Bio Tumor Immunotherapy Introduction

11.19.4 Junshi Bio Revenue in Tumor Immunotherapy Business (2019-2024)

11.19.5 Junshi Bio Recent Development

11.20 Cinda Bio

11.20.1 Cinda Bio Company Detail

11.20.2 Cinda Bio Business Overview

11.20.3 Cinda Bio Tumor Immunotherapy Introduction

11.20.4 Cinda Bio Revenue in Tumor Immunotherapy Business (2019-2024)

11.20.5 Cinda Bio Recent Development

11.21 BeiGene

11.21.1 BeiGene Company Detail

11.21.2 BeiGene Business Overview

11.21.3 BeiGene Tumor Immunotherapy Introduction

11.21.4 BeiGene Revenue in Tumor Immunotherapy Business (2019-2024)

11.21.5 BeiGene Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

Table 1. Global Tumor Immunotherapy Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Tumor Infiltrating Lymphocyte (TIL) Treatment

Table 3. Key Players of Engineered T Cell Receptor (TCR) Therapy

Table 4. Key Players of Chimeric Antigen Receptor (CAR) T Cell Therapy

Table 5. Key Players of Natural Killer (NK) Cell Therapy

Table 6. Key Players of Other

Table 7. Global Tumor Immunotherapy Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Tumor Immunotherapy Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Tumor Immunotherapy Market Size by Region (2019-2024) & (US$ Million)

Table 10. Global Tumor Immunotherapy Market Share by Region (2019-2024)

Table 11. Global Tumor Immunotherapy Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 12. Global Tumor Immunotherapy Market Share by Region (2025-2030)

Table 13. Tumor Immunotherapy Market Trends

Table 14. Tumor Immunotherapy Market Drivers

Table 15. Tumor Immunotherapy Market Challenges

Table 16. Tumor Immunotherapy Market Restraints

Table 17. Global Tumor Immunotherapy Revenue by Players (2019-2024) & (US$ Million)

Table 18. Global Tumor Immunotherapy Market Share by Players (2019-2024)

Table 19. Global Top Tumor Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunotherapy as of 2023)

Table 20. Ranking of Global Top Tumor Immunotherapy Companies by Revenue (US$ Million) in 2023

Table 21. Global 5 Largest Players Market Share by Tumor Immunotherapy Revenue (CR5 and HHI) & (2019-2024)

Table 22. Key Players Headquarters and Area Served

Table 23. Key Players Tumor Immunotherapy Product Solution and Service

Table 24. Date of Enter into Tumor Immunotherapy Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Tumor Immunotherapy Market Size by Type (2019-2024) & (US$ Million)

Table 27. Global Tumor Immunotherapy Revenue Market Share by Type (2019-2024)

Table 28. Global Tumor Immunotherapy Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 29. Global Tumor Immunotherapy Revenue Market Share by Type (2025-2030)

Table 30. Global Tumor Immunotherapy Market Size by Application (2019-2024) & (US$ Million)

Table 31. Global Tumor Immunotherapy Revenue Market Share by Application (2019-2024)

Table 32. Global Tumor Immunotherapy Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 33. Global Tumor Immunotherapy Revenue Market Share by Application (2025-2030)

Table 34. North America Tumor Immunotherapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. North America Tumor Immunotherapy Market Size by Country (2019-2024) & (US$ Million)

Table 36. North America Tumor Immunotherapy Market Size by Country (2025-2030) & (US$ Million)

Table 37. Europe Tumor Immunotherapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. Europe Tumor Immunotherapy Market Size by Country (2019-2024) & (US$ Million)

Table 39. Europe Tumor Immunotherapy Market Size by Country (2025-2030) & (US$ Million)

Table 40. Asia-Pacific Tumor Immunotherapy Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 41. Asia-Pacific Tumor Immunotherapy Market Size by Region (2019-2024) & (US$ Million)

Table 42. Asia-Pacific Tumor Immunotherapy Market Size by Region (2025-2030) & (US$ Million)

Table 43. Latin America Tumor Immunotherapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Latin America Tumor Immunotherapy Market Size by Country (2019-2024) & (US$ Million)

Table 45. Latin America Tumor Immunotherapy Market Size by Country (2025-2030) & (US$ Million)

Table 46. Middle East & Africa Tumor Immunotherapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 47. Middle East & Africa Tumor Immunotherapy Market Size by Country (2019-2024) & (US$ Million)

Table 48. Middle East & Africa Tumor Immunotherapy Market Size by Country (2025-2030) & (US$ Million)

Table 49. Roche Company Detail

Table 50. Roche Business Overview

Table 51. Roche Tumor Immunotherapy Product

Table 52. Roche Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 53. Roche Recent Development

Table 54. Merck Company Detail

Table 55. Merck Business Overview

Table 56. Merck Tumor Immunotherapy Product

Table 57. Merck Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 58. Merck Recent Development

Table 59. Novartis Company Detail

Table 60. Novartis Business Overview

Table 61. Novartis Tumor Immunotherapy Product

Table 62. Novartis Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 63. Novartis Recent Development

Table 64. Johnson & Johnson Company Detail

Table 65. Johnson & Johnson Business Overview

Table 66. Johnson & Johnson Tumor Immunotherapy Product

Table 67. Johnson & Johnson Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 68. Johnson & Johnson Recent Development

Table 69. GlaxoSmithKline Company Detail

Table 70. GlaxoSmithKline Business Overview

Table 71. GlaxoSmithKline Tumor Immunotherapy Product

Table 72. GlaxoSmithKline Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 73. GlaxoSmithKline Recent Development

Table 74. AbbVie Company Detail

Table 75. AbbVie Business Overview

Table 76. AbbVie Tumor Immunotherapy Product

Table 77. AbbVie Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 78. AbbVie Recent Development

Table 79. ELI Lilly Company Detail

Table 80. ELI Lilly Business Overview

Table 81. ELI Lilly Tumor Immunotherapy Product

Table 82. ELI Lilly Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 83. ELI Lilly Recent Development

Table 84. Amgen Company Detail

Table 85. Amgen Business Overview

Table 86. Amgen Tumor Immunotherapy Product

Table 87. Amgen Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 88. Amgen Recent Development

Table 89. AstraZeneca Company Detail

Table 90. AstraZeneca Business Overview

Table 91. AstraZeneca Tumor Immunotherapy Product

Table 92. AstraZeneca Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 93. AstraZeneca Recent Development

Table 94. Bristol-Mysers Squibb Company Detail

Table 95. Bristol-Mysers Squibb Business Overview

Table 96. Bristol-Mysers Squibb Tumor Immunotherapy Product

Table 97. Bristol-Mysers Squibb Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 98. Bristol-Mysers Squibb Recent Development

Table 99. Kite Pharma Company Detail

Table 100. Kite Pharma Business Overview

Table 101. Kite Pharma Tumor Immunotherapy Product

Table 102. Kite Pharma Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 103. Kite Pharma Recent Development

Table 104. Adaptimmune Company Detail

Table 105. Adaptimmune Business Overview

Table 106. Adaptimmune Tumor Immunotherapy Product

Table 107. Adaptimmune Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 108. Adaptimmune Recent Development

Table 109. Altor Bioscience Corporation Company Detail

Table 110. Altor Bioscience Corporation Business Overview

Table 111. Altor Bioscience Corporation Tumor Immunotherapy Product

Table 112. Altor Bioscience Corporation Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 113. Altor Bioscience Corporation Recent Development

Table 114. Cellectis Company Detail

Table 115. Cellectis Business Overview

Table 116. Cellectis Tumor Immunotherapy Product

Table 117. Cellectis Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 118. Cellectis Recent Development

Table 119. Juno Therapeutics Company Detail

Table 120. Juno Therapeutics Business Overview

Table 121. Juno Therapeutics Tumor Immunotherapy Product

Table 122. Juno Therapeutics Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 123. Juno Therapeutics Recent Development

Table 124. Takara Bio Company Detail

Table 125. Takara Bio Business Overview

Table 126. Takara Bio Tumor Immunotherapy Product

Table 127. Takara Bio Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 128. Takara Bio Recent Development

Table 129. Unum Therapeutics Company Detail

Table 130. Unum Therapeutics Business Overview

Table 131. Unum Therapeutics Tumor Immunotherapy Product

Table 132. Unum Therapeutics Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 133. Unum Therapeutics Recent Development

Table 134. Sunway Company Detail

Table 135. Sunway Business Overview

Table 136. Sunway Tumor Immunotherapy Product

Table 137. Sunway Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 138. Sunway Recent Development

Table 139. Junshi Bio Company Detail

Table 140. Junshi Bio Business Overview

Table 141. Junshi Bio Tumor Immunotherapy Product

Table 142. Junshi Bio Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 143. Junshi Bio Recent Development

Table 144. Cinda Bio Company Detail

Table 145. Cinda Bio Business Overview

Table 146. Cinda Bio Tumor Immunotherapy Product

Table 147. Cinda Bio Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 148. Cinda Bio Recent Development

Table 149. BeiGene Company Detail

Table 150. BeiGene Business Overview

Table 151. BeiGene Tumor Immunotherapy Product

Table 152. BeiGene Revenue in Tumor Immunotherapy Business (2019-2024) & (US$ Million)

Table 153. BeiGene Recent Development

Table 154. Research Programs/Design for This Report

Table 155. Key Data Information from Secondary Sources

Table 156. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Tumor Immunotherapy Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Tumor Immunotherapy Market Share by Type: 2023 VS 2030

Figure 3. Tumor Infiltrating Lymphocyte (TIL) Treatment Features

Figure 4. Engineered T Cell Receptor (TCR) Therapy Features

Figure 5. Chimeric Antigen Receptor (CAR) T Cell Therapy Features

Figure 6. Natural Killer (NK) Cell Therapy Features

Figure 7. Other Features

Figure 8. Global Tumor Immunotherapy Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 9. Global Tumor Immunotherapy Market Share by Application: 2023 VS 2030

Figure 10. Biopharmaceutical Company Case Studies

Figure 11. Hospital Case Studies

Figure 12. Universities And Other Scientific Research Institutions Case Studies

Figure 13. Other Case Studies

Figure 14. Tumor Immunotherapy Report Years Considered

Figure 15. Global Tumor Immunotherapy Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 16. Global Tumor Immunotherapy Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 17. Global Tumor Immunotherapy Market Share by Region: 2023 VS 2030

Figure 18. Global Tumor Immunotherapy Market Share by Players in 2023

Figure 19. Global Top Tumor Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunotherapy as of 2023)

Figure 20. The Top 10 and 5 Players Market Share by Tumor Immunotherapy Revenue in 2023

Figure 21. North America Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. North America Tumor Immunotherapy Market Share by Country (2019-2030)

Figure 23. United States Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Canada Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Europe Tumor Immunotherapy Market Share by Country (2019-2030)

Figure 27. Germany Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. France Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. U.K. Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Italy Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Russia Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Nordic Countries Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Asia-Pacific Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Asia-Pacific Tumor Immunotherapy Market Share by Region (2019-2030)

Figure 35. China Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Japan Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. South Korea Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Southeast Asia Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. India Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Australia Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Latin America Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Latin America Tumor Immunotherapy Market Share by Country (2019-2030)

Figure 43. Mexico Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Brazil Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Middle East & Africa Tumor Immunotherapy Market Share by Country (2019-2030)

Figure 47. Turkey Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Saudi Arabia Tumor Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. Roche Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 50. Merck Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 51. Novartis Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 52. Johnson & Johnson Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 53. GlaxoSmithKline Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 54. AbbVie Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 55. ELI Lilly Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 56. Amgen Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 57. AstraZeneca Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 58. Bristol-Mysers Squibb Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 59. Kite Pharma Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 60. Adaptimmune Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 61. Altor Bioscience Corporation Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 62. Cellectis Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 63. Juno Therapeutics Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 64. Takara Bio Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 65. Unum Therapeutics Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 66. Sunway Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 67. Junshi Bio Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 68. Cinda Bio Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 69. BeiGene Revenue Growth Rate in Tumor Immunotherapy Business (2019-2024)

Figure 70. Bottom-up and Top-down Approaches for This Report

Figure 71. Data Triangulation

Figure 72. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

120 Pages

Type: Report

Code: QYRE-Auto-14C14333

Fri Nov 08 00:00:00 UTC 2024

Add to Cart

Cancer Diagnostic Test Kits - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-28P13808

Fri Nov 08 00:00:00 UTC 2024

Add to Cart

Gamma Knife Radiosurgery (GKRS) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-29R14086

Fri Nov 08 00:00:00 UTC 2024

Add to Cart

Adult Malignant Glioma Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-12R14095

Wed Nov 06 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Tumor Immunotherapy Market Research Report 2024

Published Date: May 2024

Report Code: QYRE-Auto-18E7950

Global Tumor Immunotherapy Market Research Report 2024

FEATURED COMPANIES

Tumor Immunotherapy Market Size

Tumor Immunotherapy Market

Report Scope

Scope of Tumor Immunotherapy Market Report

Chapter Outline

FAQ for this report

Who are the main players in the Tumor Immunotherapy Market report?

What are the Application segmentation covered in the Tumor Immunotherapy Market report?

What are the Type segmentation covered in the Tumor Immunotherapy Market report?

FEATURED COMPANIES

RELATED REPORTS